William Blair downgraded Maravai Lifesciences (MRVI) to Market Perform from Outperform without a price target following the Q3 report. The company cut its EBITDA guidance “yet again,” the analyst tells investors in a research note.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai LifeSciences Reports Q3 Earnings and Strategic Acquisition
- Maravai Lifesciences reports Q3 adjusted EPS (2c), consensus (1c)
- Maravai Lifesciences lowers FY24 revenue view to $255M-$265M from $265M-$285M
- Maravai Lifesciences to acquire DNA and RNA business of Officinae Bio
- Codexis licenses genomics life science enzyme portfolio to Alphazyme